Takeda’s High-Dose TYK2 Data Could Set It Apart In Psoriasis

Safety and efficacy data show that as long as Takeda can execute effectively on a Phase III program for TAK-279, the company should be well positioned in the oral psoriasis market.

gold medal
Takeda thinks its TYK2 inhibitor could be best in class • Source: Shutterstock

Takeda Pharmaceutical Co. Ltd. investors were energized to see the detailed Phase II data results on the company’s oral TYK2 inhibitor in psoriasis, TAK-279, which appear to position Takeda as a strong competitor to Bristol Myers Squibb Company and the first-in-class entry Sotyktu (deucravacitinib) it launched in the US last year.

The Phase II data were presented at the American Academy of Dermatology annual meeting on 18 March and showed a...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category